Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 18, 2002. The report details specific corporate actions regarding share repurchases and changes in directors' interests rather than providing comprehensive financial results for a fiscal period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific share transaction:
- Share Repurchase Price: 1,250.12p per share.
- Shares Purchased: 795,000 ordinary shares.
Material Changes
The primary material change reported is the execution of a share buyback program authorized by shareholders at the Annual General Meeting on May 20, 2002. Additionally, there was a transfer of 76,255 ordinary shares from the SmithKline Beecham Employee Benefit Trust to participants of the 1991 Share Option Plan.
Management Commentary and Risks
Management commentary is limited to the announcement of the share repurchase and the notification of share transfers to the Employee Benefit Trust. The filing notes that Directors Dr. J.P. Garnier and John Coombe hold interests in the Trust shares in the same capacity as other employees. No specific risks, contingencies, or unusual items are detailed in this text.
Investor Verification Checklist
- Verify the total number of shares remaining in the authorized buyback program following the purchase of 795,000 shares.
- Confirm the impact of the 76,255 share transfers from the Employee Benefit Trust on the company's diluted share count.
- Review the full Annual Report (Form 20-F) for comprehensive financial metrics not included in this 6-K filing.